Alnylam Pharmace. buy Chardan Capital
Summary
This prediction is currently active. The prediction currently has a performance of 23.81%. This prediction currently runs until 02.05.26. The prediction end date can be changed by Chardan_Capital at any time. Chardan_Capital has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | -0.176% | -0.176% |
| iShares Core DAX® | 2,49 % | -5,94 % |
| iShares Nasdaq 100 | 1,65 % | -2,46 % |
| iShares Nikkei 225® | 0,55 % | -7,60 % |
| iShares S&P 500 | 1,35 % | -2,94 % |
Comments by Chardan_Capital for this prediction
In the thread Alnylam Pharmace. diskutieren
Stopped prediction by Chardan_Capital for Alnylam Pharmace.
Alnylam Pharmace.
25.03.26
25.03.27
01.04.26
Alnylam Pharmace.
26.02.25
26.02.26
27.02.26
Alnylam Pharmace.
11.10.24
11.10.25
12.10.25
Alnylam Pharmace.
16.02.24
16.02.25
17.02.25
Alnylam Pharmace.
08.08.23
08.08.24
09.08.24

